NEWS
Exogenus Therapeutics secures the first patent in Europe, enabling the commercial exploitation of its lead product in this region
We are pleased to announce that Exogenus Therapeutics has been granted another patent, now in Europe! This is the fifth region to recognize the patent family titled “Use of umbilical cord blood-derived exosomes for tissue repair.” This patent family has also been...
Exogenus Therapeutics Chooses Lonza to Develop a GMP-Compliant Process to Manufacture Exo-101, its Lead Exosome-Based Candidate
Exogenus Therapeutics Chooses Lonza to Develop a GMP-Compliant Process to Manufacture Exo-101, its Lead Exosome-Based Candidate Lonza to develop a GMP-compliant process for Exo-101 manufacturing from its Siena (IT) site Exo-101 has shown safety and efficacy in...
Exogenus Therapeutics secures second patent in Japan, which enables the commercial exploitation of its lead product in this region
We are pleased to announce that ExogenusTherapeutics has been granted another patent in Japan! This is the second patent granted in this region, and the first one to be granted within the family entitled "Compositions comprising small extracellular vesicles derived...
Join Exogenus Therapeutics at Exosomes Europe
Joana Correia, Founder and CEO of Exogenus Therapeutics, will be a featured speaker at Exosomes Europe, taking place in London on June 5th and 6th. Joana will present a talk titled "Extracellular vesicles in human health: opportunities and challenges," where she...
Exogenus Therapeutics secures funding to accelerate pipeline
Exogenus Therapeutics is proud to announce a strategic investment led by 3xP Global. This funding of 3xP Global will significantly advance the development of Exogenus lead product, Exo-101, that derived from umbilical cord blood cells and has shown promise in multiple...
Exogenus Therapeutics participated in a roundtable about “Diagnostic &therapeutic uses for extracellular vesicles (EVs)”
Exogenus Therapeutics CEO, Joana Simões Correia, participated in a roundtable organized by Cell &Gene Therapy Insights and Miltenyi, as part of a discussion panel about “Diagnostic &therapeutic uses for extracellular vesicles (EVs): insights into a rapidly...
Exogenus Therapeutics is co-author of the new ISEV report
A meeting report from the 2021 massivEVs workshop entitled “Large-scale production of extracellular vesicles: Report on the “massivEVs” ISEV workshop” is now online. The massivEVs workshop took place on October 2021 and addressed the efforts towards large scale EV...
Exogenus Therapeutics is one of the winners of this year’s Blue Bio Value Accelerator
We are proud to be awarded at the 5th Blue Bio Value Accelerator, which included the participation of 18 selected startups from 12 countries. This international cohort focused on innovative solutions aligned with blue economy principles. Organized by Oceano Azul...
Exogenus Therapeutics strengthens IP portfolio with patent granted in China and Korea
Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in China and Korea. The patent describes the use of extracellular vesicles secreted by umbilical cord blood...
Exogenus Therapeutics participates in Blue Bio Value’s Accelerator, aiming to bring blue-derived EV to the healthcare market
Exogenus Therapeutics was one of the 18 startups selected to take part in the Blue Bio Value Accelerator organized by Oceano Azul Foundation, Calouste Gulbekian Foundation and Maze. The accelerator aims to train and promote international startups working in the blue...
Join Joana Correia at the 4th Exosome Based Therapeutic Development Summit
Exogenus Therapeutics CEO, Joana Simões Correia, is again an invited speaker at the 4th Exosome Based Therapeutic Development Summit, taking place in Boston, October 4th-6th. Joana’s talk will focus on the importance of EV quality control and on the therapeutic...
Is Portugal a driver for innovation in biotech? Labiotech highlights inspiring companies, including Exogenus Therapeutics.
Labiotech, a Berlin-based digital media company covering biotech, recently published an article highlighting Portuguese success stories, which include Exogenus Therapeutics and other “neighbors” headquartered in Biocant (Cantanhede), such as Immunethep and...
Get to know Joana Correia at the IX BiotechHealth Annual Symposium
Joana Correia, Exogenus’s co-founder, CEO and CSO is an invited speaker at the IX BiotechHealth Annual Symposium, organized by i3S and taking place on June 28th 2022. Joana will be taking us on a trip from her days as an academic researcher to founding and...
Congratulations to the InnoCore participants!
Today the final event of the InnoCore Challenge took place in Granada, Spain. Teams of MSc and PhD students were challenged to propose solutions for real problems faced by companies. Instead of focusing only on the scientific solutions, the teams also had to estimate...
Exogenus Therapeutics announces collaboration with Boehringer Ingelheim to explore the use of extracellular vesicles in regenerative medicine applications
images/Press-Release-Boehringer-Exogenus-Therapeutics-300 ×150.png
Exogenus Therapeutics selected to be part of the InnoCore Challenge
Exogenus Therapeutics is one of the five companies presenting projects in the Innocore Challenge. The initiative is part of the project “InnoCore – Core Technologies for Education and Innovation in Life Sciences”, funded by the Erasmus+ programme, and combines...
Joana Simões Correia is an invited speaker at the 3rd Exosome Based Therapeutic Development Summit
Exogenus Therapeutics CEO, Joana Simões Correia, is again an invited speaker at the 3rd Exosome Based Therapeutic Development Summit, taking place virtually on November 17th and 18th, as part of a panel discussion about "Comparing Engineered &Naturally Derived...
Exogenus Therapeutics joins the massivEVs workshop to share insights about Exo-101’s production process and composition
Our team member Carla Pereira will be attending the massivEVs workshop, organized by ISEV, with a poster titled “Manufacturing and characterization of extracellular vesicles from umbilical cord mononuclearcells for future clinical use”. She will be sharing published...
Exogenus Therapeutics receives 1st Place in the category of BioTech at the 2021 Go Global Awards
Exogenus Therapeutics was announced as 1st Place in the category of BioTech on the 14th October 2021, at the International Trade Council's Annual Go Global Awards Ceremony. Founded in 2015, Exogenus Therapeutics is an early-stage R &D biotech company, dedicated to...
Exogenus Therapeutics strengthens IP portfolio with patent granted in Japan
Exogenus Therapeutics announces that its exclusively licensed patent entitled “USE OF UMBILICAL CORD BLOOD DERIVED EXOSOMES FOR TISSUE REPAIR” has been granted in Japan. The patent describes the use of exosomes naturally secreted by umbilical cord blood mononuclear...
New study highlights Exo-101’s potential for inflammatory skin diseases
A recent study published in the Journal of Molecular Sciences illustrates how Exo-101 modulates cells and their microenvironment, to reduce inflammation and promote homeostasis. These results support the development of Exo-101 as an adjuvant therapy for inflammatory...
Exogenus Therapeutics publishes study detailing Exo-101’s safety profile
Exogenus published a study offering an in-depth look at the safety profile of umbilical cord blood-derived exosomes. Exo-101, a solution enriched in small extracellular vesicles produced by umbilical cord blood mononuclear cells (UCB-MNC-sEV), has consistently shown...
Exogenus Therapeutics presents at ISEV Annual Meeting 2021
Patricia Freire, one of Exogenus’ scientists, presents some of our recent advances at the ISEV Annual Meeting, happening on May 18th to 21st, virtually. The talk, entitled “Umbilical cord blood-derived small extracellular vesicles: immune-modulating properties and...
Exogenus Therapeutics selected to present at the European Innovation Council’s Investor Day on Health
Exogenus was the only Portuguese company selected to pitch at the European Innovation Council’s Investor Day on Health on May 18th and 19th to present its pioneering technology to leading Life Sciences investors from across the globe, featuring its Series A investment...
Labiotech.eu just published an article featuring the interview with Exogenus’ CEO and CSO, Joana Correia, discussing the disparity in funding opportunities seen in Europe vs USA. The article, which also quotes Antonin de Fougerolles (Evox Therapeutics, CEO) and...
Our recent publication featured in Exosome RNA
Exosome RNA, an online publication featuring the hottest trends in global exosome research, recently highlighted Exogenus Therapeutics’ contribution to the field, by mentioning our recent publication in Stem Cells Translational Medicine. Exogenus Therapeutics...
Exogenus Therapeutics featured in Labiotech’s article
Labiotech.eu, a biotechnology-centered online issue, published an article about exosomes, featuring Exogenus Therapeutics as one of the leading exosome biotechnology companies in Europe. The piece delves into the most recent advances in exosome-based therapeutics and...